Discovery of 6-Deoxydapagliflozin as a Highly Potent Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Lingyu Zhang, Yuli Wang, Huaqiang Xu, Yongheng Shi, Bingni Liu, Qunchao Wei, Weiren Xu, Lida Tang, Jianwu Wang and Guilong ZhaoAffiliation:
School of Chemistry and Chemical Engineering, Shandong University, Jinan 250100, P.R. China and Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, 308 An Shan Xi Dao, Nankai District, Tianjin 300193, P.R. China.
AbstractSystematic mono-deoxylation of the four hydroxyl groups in the glucose moiety in dapagliflozin led to the discovery of 6-deoxydapagliflozin 1 as a more active sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor (IC50 = 0.67 nM against human SGLT2 (hSGLT2) vs 1.16 nM for dapagliflozin). It exhibited more potent blood glucose inhibitory activity in rat oral glucose tolerance test and induced more urinary glucose in rat urinary glucose excretion test than its parent compound dapagliflozin.
Dapagliflozin, deoxy, SGLT2 inhibitor, synthesis.
Purchase Online Rights and Permissions